Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Titre officiel

Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) in Combination With Bendamustine (TREanda) in Relapsed/Refractory Hodgkin Lymphoma

Sommaire:

Il s’agit d’une étude ouverte de phase II visant à tester l’inocuité et l’efficacité de l’association du pembrolizumab et de la bendamustine chez les patients atteints d’un lymphome de Hodgkin récidivant (cancer qui est revenu ou a commencé à s’aggraver) ou réfractaire (cancer qui ne répond pas ou a cessé de répondre au traitement).

Description de l'essai

Primary Outcome:

• Overall response rate
• Complete response rate as determined by Lugano criteria

Secondary Outcome:

• Incidence of adverse events
• Overall survival rate
• Progression-free survival rate
• Average duration of response

Pembrolizumab and bendamustine will be explored as a safe and effective treatment for these patients.

Although current treatment options are available for patients in the relapsed state, once these therapies fail or are not tolerated, treatment options are quite limited.

Pembrolizumab and bendamustine have both shown activity when used as a single agent as treatment for Hodgkin Lymphoma. Their side effect profiles also do not overlap, which makes them ideal to combine, with an intent to increase the amount and duration of complete responses while limiting the toxicities experienced by patients.

Voir cet essai sur ClinicalTrials.gov